ES545247A0 - Un procedimiento para obtener un polidoma - Google Patents

Un procedimiento para obtener un polidoma

Info

Publication number
ES545247A0
ES545247A0 ES545247A ES545247A ES545247A0 ES 545247 A0 ES545247 A0 ES 545247A0 ES 545247 A ES545247 A ES 545247A ES 545247 A ES545247 A ES 545247A ES 545247 A0 ES545247 A0 ES 545247A0
Authority
ES
Spain
Prior art keywords
polydoma
procedure
obtaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES545247A
Other languages
English (en)
Other versions
ES8607386A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of ES8607386A1 publication Critical patent/ES8607386A1/es
Publication of ES545247A0 publication Critical patent/ES545247A0/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES545247A 1982-04-12 1985-07-16 Un procedimiento para obtener un polidoma Expired ES8607386A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36778482A 1982-04-12 1982-04-12

Publications (2)

Publication Number Publication Date
ES8607386A1 ES8607386A1 (es) 1986-05-16
ES545247A0 true ES545247A0 (es) 1986-05-16

Family

ID=23448582

Family Applications (7)

Application Number Title Priority Date Filing Date
ES521370A Granted ES521370A0 (es) 1982-04-12 1983-04-11 Un procedimiento para obtener un polidoma.
ES527963A Expired ES8503441A1 (es) 1982-04-12 1983-12-12 Un procedimiento de inmunoensayo
ES533930A Granted ES533930A0 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES533931A Expired ES8506091A1 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES537257A Expired ES8606655A1 (es) 1982-04-12 1984-10-31 Un procedimiento de inmunoensayo
ES538727A Expired ES8604424A1 (es) 1982-04-12 1984-12-18 Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983
ES545247A Expired ES8607386A1 (es) 1982-04-12 1985-07-16 Un procedimiento para obtener un polidoma

Family Applications Before (6)

Application Number Title Priority Date Filing Date
ES521370A Granted ES521370A0 (es) 1982-04-12 1983-04-11 Un procedimiento para obtener un polidoma.
ES527963A Expired ES8503441A1 (es) 1982-04-12 1983-12-12 Un procedimiento de inmunoensayo
ES533930A Granted ES533930A0 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES533931A Expired ES8506091A1 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES537257A Expired ES8606655A1 (es) 1982-04-12 1984-10-31 Un procedimiento de inmunoensayo
ES538727A Expired ES8604424A1 (es) 1982-04-12 1984-12-18 Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983

Country Status (11)

Country Link
EP (1) EP0105360A4 (es)
JP (2) JPH0753119B2 (es)
AT (1) AT394577B (es)
AU (1) AU550486B2 (es)
CA (1) CA1213229A (es)
CH (1) CH672796A5 (es)
ES (7) ES521370A0 (es)
FI (2) FI900212A0 (es)
GB (4) GB2128631B (es)
IT (1) IT1219778B (es)
WO (1) WO1983003679A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3177776B2 (ja) * 1988-09-27 2001-06-18 武田薬品工業株式会社 ハイブリッドモノクローナル抗体,抗体産生ポリドーマおよび抗体含有薬剤
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
IL70686A (en) * 1983-01-20 1988-07-31 Suntory Ltd Mutant tumor cell lines for use in the preparation of hybridomas and the hybridomas obtained therefrom
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
EP0467416A1 (en) * 1983-09-01 1992-01-22 Hybritech Incorporated Antibody compositions of therapeutic agents having an extended serum half-life
JPH0617909B2 (ja) * 1984-04-23 1994-03-09 ボストン バイオメディカル リサーチ インスティテュート,インコーポレイテッド 双特異性抗体決定子
NL8501219A (nl) * 1985-04-29 1986-11-17 Stichting Vrienden Van De Stic Immunologisch complex, de bereiding en toepassing daarvan.
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
JP2635343B2 (ja) 1986-04-14 1997-07-30 ザ・ジェネラル・ホスピタル・コーポレーション ヘテロ二官能性抗体および利用方法
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
US5053226A (en) * 1987-07-15 1991-10-01 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
ES2058199T3 (es) * 1987-09-23 1994-11-01 Bristol Myers Squibb Co Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih.
GB2218100A (en) * 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
US4892824A (en) * 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
JPH02196799A (ja) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol 抗ヒト癌蛋白複合体
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
IT1235349B (it) * 1988-12-23 1992-06-30 Biodata Spa Saggio immunologico per determinazioni in fase omogenea
CA2006408A1 (en) * 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
US5217713A (en) * 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
WO1990012109A1 (en) * 1989-03-30 1990-10-18 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
FR2652004B1 (fr) * 1989-09-21 1994-10-28 Immunotech Partners Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.
DE69130561T2 (de) * 1990-02-16 1999-06-24 Boston Biomedical Research Institute, Inc., Boston, Mass. Hybride Reagenzien mit der Fähigkeit, Moleküle selektiv in Zellen freizusetzen
TW212184B (es) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
DE69214709T2 (de) * 1991-04-26 1997-02-20 Surface Active Ltd Neue Antikörper und Verfahren zu ihrer Verwendung
GB9316369D0 (en) * 1993-08-06 1993-09-22 Surface Active Ltd Diagnostic method
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
GB9421468D0 (en) * 1994-10-18 1994-12-07 Surface Active Ltd Biosensor
US20030017147A1 (en) * 1996-09-20 2003-01-23 Guy L Reed Composition and method for enhancing fibrinolysis
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
WO2005089269A2 (en) 2004-03-16 2005-09-29 Temple University - Of The Commonwealth System Of Higher Education Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders
EP3505191A1 (en) 2004-11-12 2019-07-03 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
CN101203241B (zh) 2005-04-19 2012-02-22 西雅图基因公司 人源化抗-cd70结合物和其应用
DK1912671T3 (da) 2005-07-18 2017-11-27 Seattle Genetics Inc Beta-glucuronid-linker-lægemiddelkonjugater
DK2099823T4 (da) 2006-12-01 2022-05-09 Seagen Inc Målbindingsmiddelvarianter og anvendelser deraf
MX2009007632A (es) 2007-01-22 2009-07-24 Genentech Inc Precipitacion de polielectrolito y purificacion de proteinas.
ES2458541T5 (en) 2008-05-02 2025-08-04 Seagen Inc Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
AU2014228489B2 (en) 2013-03-15 2018-11-15 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
JP6473418B2 (ja) 2013-10-10 2019-02-20 幸成 加藤 抗ポドプラニン抗体
DK3086815T3 (da) 2013-12-27 2022-05-23 Zymeworks Inc Sulfonamidholdige forbindelsessystemer til lægemiddelkonjugater
RU2723651C2 (ru) 2014-09-17 2020-06-17 Займворкс Инк. Цитотоксические и антимитотические соединения и способы их применения
EP3165532B1 (en) 2015-11-03 2018-12-19 Industrial Technology Research Institute Auristatin derivatives, linker-drugs and ligand-drug conjugates
MA43835A (fr) 2016-03-25 2018-11-28 Seattle Genetics Inc Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
KR102648564B1 (ko) 2017-03-24 2024-03-19 씨젠 인크. 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
JP7156653B2 (ja) * 2018-08-30 2022-10-19 イノベイティブ セルラー セラピューティクス ホールディングス,エルティディ 固形腫瘍を治療するためのキメラ抗原受容体細胞
CA3139809A1 (en) 2019-05-10 2020-11-19 Takeda Pharmaceutical Company Limited Antibody drug conjugates
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗-cd70抗體治療癌症之方法
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
EP4240488A1 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Antibody drug conjugates
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
AU2022304582A1 (en) 2021-06-29 2024-02-01 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130634A (en) * 1974-03-15 1978-12-19 University Of Illinois Foundation Method for detecting and quantifying antigens
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies

Also Published As

Publication number Publication date
GB2168998A (en) 1986-07-02
AT394577B (de) 1992-05-11
IT8320548A0 (it) 1983-04-12
GB2169921A (en) 1986-07-23
JPH0753119B2 (ja) 1995-06-07
GB8530309D0 (en) 1986-01-22
ES8607386A1 (es) 1986-05-16
ES538727A0 (es) 1986-02-01
ES8604424A1 (es) 1986-02-01
GB8530308D0 (en) 1986-01-22
GB2128631B (en) 1987-02-25
GB2167086B (en) 1987-03-04
ES8606655A1 (es) 1986-04-01
GB2128631A (en) 1984-05-02
CA1213229A (en) 1986-10-28
CH672796A5 (es) 1989-12-29
ES533931A0 (es) 1985-06-16
JPH0753600A (ja) 1995-02-28
ES527963A0 (es) 1985-02-16
GB2167086A (en) 1986-05-21
EP0105360A1 (en) 1984-04-18
ES8503441A1 (es) 1985-02-16
ES8506091A1 (es) 1985-06-16
ES8603080A1 (es) 1985-12-01
ES8504461A1 (es) 1985-04-16
GB2168998B (en) 1987-03-04
FI834529L (fi) 1983-12-09
EP0105360A4 (en) 1986-07-08
FI834529A7 (fi) 1983-12-09
JP2562002B2 (ja) 1996-12-11
IT1219778B (it) 1990-05-24
FI900212A7 (fi) 1990-01-15
ATA901883A (de) 1991-10-15
GB2169921B (en) 1987-03-04
GB8530310D0 (en) 1986-01-22
ES533930A0 (es) 1985-12-01
GB8332646D0 (en) 1984-01-11
AU550486B2 (en) 1986-03-20
JPS6312276A (ja) 1988-01-19
FI834529A0 (fi) 1983-12-09
FI900212A0 (fi) 1990-01-15
ES537257A0 (es) 1986-04-01
WO1983003679A1 (en) 1983-10-27
ES521370A0 (es) 1985-04-16
AU1555983A (en) 1983-11-04

Similar Documents

Publication Publication Date Title
ES545247A0 (es) Un procedimiento para obtener un polidoma
ES500726A0 (es) Un procedimiento para preparar diaminopiridinas
ES532538A0 (es) Un procedimiento para preparar un derivado de carbostirilo
ES537668A0 (es) Un procedimiento para preparar n-formil-3-fenoxi-1-azetidincarboxamidas
ES523195A0 (es) Un procedimiento para preparar alquil-glicosidos
ES530024A0 (es) Un procedimiento para preparar derivados de pirazinona
ES527790A0 (es) Un procedimiento para preparar nuevos compuestos de cefem
ES500727A0 (es) Un procedimiento para preparar imidazo-piridinas
ES545270A0 (es) Un procedimiento para la obtencion de piridoindoles
ES528304A0 (es) Un procedimiento para preparar derivados de pirimidona
ES528003A0 (es) Un procedimiento para preparar derivados de cefem
ES519652A0 (es) Un procedimiento para obtener s-adenosil-metionina.
ES524245A0 (es) Procedimiento para obtener un polipeptido
ES523193A0 (es) Un procedimiento para preparar 3-fenoxi-1-azetidincarbo-xznmidas
MX163078B (es) Procedimiento mejorado para formar nitroparafinas
ES525007A0 (es) Un procedimiento para producir derivados de tiazol
ES539082A0 (es) Un procedimiento para preparar compuestos peptidicos sustituidos
ES527278A0 (es) Un procedimiento para obtener 2,5-anhidro-3,4,6-tri-o-acil-d-alonselenocarboxamida
ES526177A0 (es) Un procedimiento para preparar derivados de pirimidona
ES500464A0 (es) Un procedimiento para preparar 2-halogeno-acetanilidas
ES527108A0 (es) Un procedimiento para preparar 2-alcoxi-5-(piridinil) piridinas
ES527738A0 (es) Un procedimiento para preparar derivados de piridona
ES525647A0 (es) Un procedimiento para preparar compuestos de benzoilurea
ES518376A0 (es) Un procedimiento para preparar nuevas nitro-n-fenilpiridinaminas
ES527789A0 (es) Un procedimiento para preparar derivados de cicloalquenilo

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970401